# Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults

> **NCT01997632** · PHASE1 · COMPLETED · sponsor: **University Hospital, Ghent** · enrollment: 120 (actual)

## Conditions studied

- Poliomyelitis

## Interventions

- **BIOLOGICAL:** a single dose of monovalent high-dose inactivated poliovirus type 2 vaccine (m-IPV2 HD)
- **BIOLOGICAL:** a single dose of the standard trivalent inactivated poliovirus vaccine (IPV)(Imovax Polio®).

## Key facts

- **NCT ID:** NCT01997632
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2015-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01997632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01997632, "Phase 1 Study on the Safety and Reactogenicity of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) Given Intramuscularly Compared to Standard Trivalent Inactivated Poliovirus Vaccine (IPV) in Healthy Adults". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01997632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*